Back Pain News and Research

Latest Back Pain News and Research

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Celgene International Sàrl today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma either with a germinal center B-cell or non-germinal center B-cell phenotype.

5 Jun 2010

Anulex Technologies completes $20M Series E financing round

Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.

4 Jun 2010

Tips to prevent back injuries

Whether moving to a new home or packing up for the semester, the physical intensity of moving can be extreme. Packing boxes, moving heavy furniture, emptying overhead cabinets -- all come with some risk for injury, especially to your back. Back pain is one of the most common reasons for Americans visit their doctors.

3 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

FDA approves Prolia for postmenopausal women with osteoporosis

The U.S. Food and Drug Administration approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

2 Jun 2010

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

1 Jun 2010

Smartfish announces second distribution partnership with Mobility Lab for ErgoMotion technology

Today from Medpi 2010, Smartfish Technologies announced its second strategic partnership to distribute and sell its ErgoMotion™ technology with Mobility Lab of France. As part of its agreement with Mobility Lab, Smartfish will provide its award-winning ErgoMotion technology to Mobility Lab for distribution to retailers in France, Switzerland, Netherlands, Belgium, Luxemburg and Spain. Smartfish will manufacture the resulting Mobility Lab branded products powered by ErgoMotion.

28 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

In this economy, allergy sufferers are looking for relief from more than sneezing, runny noses, and itchy eyes. And, according to a recent study, they can find relief for both their symptoms and their wallets, saving anywhere from $50 to $400 in out-of-pocket costs per visit if they skip the emergency room and head to urgent care and retail health clinics when they are unable to see their primary physician.

20 May 2010

Pain rehabilitation programs can help patients break the cycle of worsening pain: Mayo Clinic Health Letter

Chronic pain -- whether from headaches, back pain or conditions such as fibromyalgia -- can interfere with work, day-to-day activities and relationships. All too often, pain relief treatments are ineffective and can lead to a downward spiral of frustration, decreased functioning, stress, isolation -- and worsening pain.

13 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

10 May 2010

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

Back Pain News and Research

Latest Back Pain News and Research

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Anulex Technologies completes $20M Series E financing round

Tips to prevent back injuries

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

FDA approves Prolia for postmenopausal women with osteoporosis

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Smartfish announces second distribution partnership with Mobility Lab for ErgoMotion technology

Genentech to present new data for targeted cancer medicines at 46th ASCO

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

Pain rehabilitation programs can help patients break the cycle of worsening pain: Mayo Clinic Health Letter

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

DXA testing can prevent osteoporosis in at-risk women

Southeast Pain Care offers non-addictive alternatives to pain relief

FDA approves Provenge for treating men with advanced prostate cancer

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Back Pain News and Research

Latest Back Pain News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in